CRINETICS PHARMACEUTICALS IN (CRNX) Stock Overview
USA - NASDAQ:CRNX - US22663K1079 - Common Stock
CRNX Key Statistics, Chart & Performance
The current stock price of CRNX is 33.91 USD. In the past month the price increased by 15.34%. In the past year, price decreased by -36.2%.
CRNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.56 | 711.73B | ||
| JNJ | JOHNSON & JOHNSON | 17.62 | 424.33B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.62 | 272.83B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.89 | 237.97B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.18 | 236.50B | ||
| MRK | MERCK & CO. INC. | 10.59 | 203.59B | ||
| PFE | PFIZER INC | 7.09 | 136.62B | ||
| SNY | SANOFI-ADR | 10.71 | 116.19B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.69 | 91.64B | ||
| GSK | GSK PLC-SPON ADR | 9 | 81.93B | ||
| ZTS | ZOETIS INC | 23.45 | 64.65B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.93 | 47.56B |
Related stock screener links
About CRNX
Company Profile
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 437 full-time employees. The company went IPO on 2018-07-18. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Company Info
CRINETICS PHARMACEUTICALS IN
6055 Lusk Blvd.
San Diego CALIFORNIA 92121 US
CEO: R. Scott Struthers
Employees: 437
Phone: 18584506464
CRINETICS PHARMACEUTICALS IN / CRNX FAQ
What is the stock price of CRINETICS PHARMACEUTICALS IN today?
The current stock price of CRNX is 33.91 USD. The price decreased by -4.43% in the last trading session.
What is the ticker symbol for CRINETICS PHARMACEUTICALS IN stock?
The exchange symbol of CRINETICS PHARMACEUTICALS IN is CRNX and it is listed on the Nasdaq exchange.
On which exchange is CRNX stock listed?
CRNX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CRINETICS PHARMACEUTICALS IN stock?
24 analysts have analysed CRNX and the average price target is 72.64 USD. This implies a price increase of 114.21% is expected in the next year compared to the current price of 33.91. Check the CRINETICS PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CRINETICS PHARMACEUTICALS IN worth?
CRINETICS PHARMACEUTICALS IN (CRNX) has a market capitalization of 3.19B USD. This makes CRNX a Mid Cap stock.
How many employees does CRINETICS PHARMACEUTICALS IN have?
CRINETICS PHARMACEUTICALS IN (CRNX) currently has 437 employees.
What are the support and resistance levels for CRINETICS PHARMACEUTICALS IN (CRNX) stock?
CRINETICS PHARMACEUTICALS IN (CRNX) has a support level at 33.9 and a resistance level at 35.47. Check the full technical report for a detailed analysis of CRNX support and resistance levels.
Is CRINETICS PHARMACEUTICALS IN (CRNX) expected to grow?
The Revenue of CRINETICS PHARMACEUTICALS IN (CRNX) is expected to grow by 252.26% in the next year. Check the estimates tab for more information on the CRNX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CRINETICS PHARMACEUTICALS IN (CRNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRNX, evaluating the profitability, health, valuation and growth aspects
- CRINETICS PHARMACEUTICALS IN (CRNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CRINETICS PHARMACEUTICALS IN (CRNX) Sales and EPS estimates to see what analysts future expectations are.
- CRINETICS PHARMACEUTICALS IN (CRNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CRINETICS PHARMACEUTICALS IN (CRNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- CRINETICS PHARMACEUTICALS IN (CRNX) Stock Chart to make your own analysis
- CRINETICS PHARMACEUTICALS IN (CRNX) Latest news and press-releases to stay up to date.
Does CRINETICS PHARMACEUTICALS IN (CRNX) stock pay dividends?
CRNX does not pay a dividend.
When does CRINETICS PHARMACEUTICALS IN (CRNX) report earnings?
CRINETICS PHARMACEUTICALS IN (CRNX) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of CRINETICS PHARMACEUTICALS IN (CRNX)?
CRINETICS PHARMACEUTICALS IN (CRNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.11).
What is the Short Interest ratio of CRINETICS PHARMACEUTICALS IN (CRNX) stock?
The outstanding short interest for CRINETICS PHARMACEUTICALS IN (CRNX) is 15.34% of its float. Check the ownership tab for more information on the CRNX short interest.
CRNX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CRNX. When comparing the yearly performance of all stocks, CRNX is a bad performer in the overall market: 85.07% of all stocks are doing better.
CRNX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRNX. No worries on liquidiy or solvency for CRNX as it has an excellent financial health rating, but there are worries on the profitability.
CRNX Financial Highlights
Over the last trailing twelve months CRNX reported a non-GAAP Earnings per Share(EPS) of -4.11. The EPS decreased by -8.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.68% | ||
| ROE | -31.57% | ||
| Debt/Equity | 0 |
CRNX Forecast & Estimates
24 analysts have analysed CRNX and the average price target is 72.64 USD. This implies a price increase of 114.21% is expected in the next year compared to the current price of 33.91.
For the next year, analysts expect an EPS growth of -30.76% and a revenue growth 252.26% for CRNX